With the Coronavirus raging, we’re all on the edge of our seats to know as much as possible.
Johnson and Johnson (JNJ) said Monday that it will have human testing for a vaccine as early as September. Other big players are getting in on the act, and that doesn't exclude small players with some serious bite.
Fortunately, we at TheStreet have had the opportunity to talk to people in the know.
Let’s dive right in.
A company produces a drug and then tests the drug internally, sometimes on animals. Drugs can’t be tested on people until its tested in other forms and reviewed by the Food and Drug Administration.
Then, the company send the results to FDA’s Center for Drug Evaluation and Research. The CDER’s job is to use its scientists, chemists and medical experts to discern if the drug’s benefits outweigh the risks.
They are evaluating the drug on all fronts and making sure the risk-reward scenario is a positive one for people who need treatment.
Then, if it’s safe, the company will test the drug on people.
If the FDA approves of the drug, the company can bring it to market for sale.
Sow here does the Coronavirus vaccine stand in all of this? Watch two things: the video above and TheStreet's interview with Emergent BioSolutions CEO, Bob Kramer.
Catch up on the Latest Videos on TheStreet!
- ‘We’re at War:’ Trump on Coronavirus in New York, Washington, California, Rand Paul, Economy
- Where Stocks Finished the Week, What Wall Street Says to Do Now
- How This Small Biotech Player Is Racing Gilead, Moderna to Coronavirus Treatment
- A Legal Look at the Drugs Being Used to Potentially Treat Coronavirus